A5211: PHASE II OF SCH417690, ORAL HIV-1 ENTRY INHIBITOR IN HIV

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 假设：在艾滋病毒感染、有治疗经验的患者中，SCH 417690将是安全的，通常耐受性良好，并与含有利托那韦的抗逆转录病毒疗法同时使用时显示出抗逆转录病毒活性。 主要目的：评估三个剂量水平的SCH 417690在14天内的病毒学活性，这些患者是艾滋病毒感染者，有治疗经验，但目前的利托那韦抗逆转录病毒治疗方案失败。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Hypothesis: In HIV-infected, treatment-experienced patients, SCH 417690 will be safe, be generally well-tolerated, and demonstrate antiretroviral activity when used concurrently with a ritonavir-containing antiretroviral regimen. Primary Objective: To evaluate the virologic activity over 14 days of three dose levels of SCH 417690 in HIV-infected, treatment-experienced subjects who are failing their current ritonavir-containing antiretroviral regimen.